Background: Adjuvant chemotherapy reduces recurrences of nonsmall-cell lung cancer (NSCLC). To determine which patients need adjuvant chemotherapy, we assessed factors associated with time to relapse (TTR). Methods: In 230 resected stage I-II NSCLCs, we correlated immunohistochemistry scores for factors associated with cell growth rate, growth regulation, hypoxia, cell survival, and cell death with TTR. Results: With a median follow-up of 82 months (1-158) for those alive and relapse free at last follow-up, median time to recurrence was not reached. The 2-and 5-year probabilities of maintaining freedom from recurrence were 80.7% (95% confidence interval, 75.3%, 86.4%) and 74.6% (95% confidence interval, 68.6%, 81.2%), respectively. TTR curves flattened at an apparent cure rate of 70%. In multicovariate Cox models, factors correlating with shorter TTR were membranous carbonic anhydrase IX (mCAIX) staining (any versus none, hazard ratio = 2.083, p = 0.023) and node stage (N1 versus N0, hazard ratio = 2.591, p = 0.002). mCAIX scores correlated positively with tumor size, grade, squamous histology, necrosis, mitoses, Ki67, p53, nuclear DNA methyltransferase 1, and cytoplasmic enhancer-of-split-and-hairy-related protein, and they correlated inversely with papillary histology, epidermal growth factor receptor mutation (trend), copper transporter-1, and cytoplasmic hypoxia-inducible factor-1α, vascular endothelial growth factor, DNA methyltransferase 1, and excision repair cross-complementing rodent repair deficiency, complementation group 1. Conclusion: Nodal stage and mCAIX immunohistochemistry were the strongest independent predictors of shorter TTR in resected NSCLCs. mCAIX correlated with tumor size, markers of tumor proliferation and necrosis, and tumor genetic characteristics, and it paradoxically correlated inversely with the hypoxia markers, hypoxia-inducible factor-1α and vascular endothelial growth factor. Presence of mCAIX could help determine patients with high risk of recurrence who might require adjuvant chemotherapy.
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and U.S. lung cancer 5-year relative survival rate has only increased from 12% in 1975-1977 to 16% currently. 2 The poor prognosis of lung cancer is due in part to a high proportion of patients presenting initially with advanced disease, but even patients with operable early-stage disease are at moderately high risk of relapse. 3 Adjuvant chemotherapy reduces the probability of relapse after lung cancer resection, but we are currently not able to accurately determine which patients actually need adjuvant therapy. In patients with resected stage I and II non-small-cell lung cancer (NSCLC), we assessed association with time to relapse (TTR) and overall survival (OS) of various tumor markers related to tumor growth rate, growth control, tumor cell survival and death, and hypoxia. In defining clinically important biomarkers to predict tumor biological behavior, OS is a more precise end point than TTR, but it has the major disadvantage that it is affected by several factors unrelated to tumor biology, including patient age, comorbidities, and therapy details. 4 Hence, our primary objective was to define factors associated with TTR (defined as the time from surgery to tumor recurrence, with patients censored at time of last follow-up (LFU), death from other causes, or development of a new primary malignancy [in lung or any other site] that was associated with metastases, if they remained free of evidence of recurrence of their initial primary lung cancer at that time).
had given informed consent at the time of tissue collection and who had not received any adjuvant or neoadjuvant chemotherapy or radiotherapy.
Tissue microarrays (TMAs) were prepared using standard methods 5 : a biopsy needle was inserted into each formalin-fixed, paraffin-embedded tumor specimen three times to obtain three tissue cores, each measuring 1 mm in diameter by 2 to 3 mm long. Based on prior assessment of hematoxylin and eosin slides, the TMA cores were obtained preferentially from areas with high tumor cell content and with minimal necrosis or fibrosis, with one sample taken from around the center of the tumor, one from the periphery, and one from an intermediate area. Serial sections were cut from the TMA constructed from these cores and mounted on glass slides. Slides were deparaffinized in Xylene for 10 minutes three times. The tissue sections were hydrated in graded ethanols 100%, 90%, 70%, and 50% for 5 minutes each time. Heat-induced epitope retrieval was performed in a Dako (Carpinteria, CA) antigen retrieval bath at 121°C for 30 minutes and 90°C for 10 minutes using a Decloaking chamber (Biocare, Concord, CA), followed by a 30 minutes cool down. Before antibody immunostaining, endogenous peroxidase activity was blocked with 3% H 2 O 2 in methanol for 30 minutes. To block nonspecific antibody binding, tissue sections were incubated with 10% fetal bovine serum in Tris Buffered Saline in Tween 20 for 30 minutes. Incubation with primary antibodies is as presented in Supplementary Table 1 (Supplemental Digital Content 1, http://links.lww.com/JTO/A547). This was followed by incubation with Envision plus labeled polymer, anti-rabbit-horseradish-peroxidase antibody (Dako) for 30 minutes at room temperature. Staining development was performed with diaminobenzidine, with timed monitoring using a positive control sample. The slides were then counterstained with hematoxylin, dehydrated, cleared, and mounted.
Experienced lung pathologists (MIN and IIW, blinded for patient outcome) then manually recorded percent of tumor cells staining with 0 (absent), 1+ (mild), 2+ (moderate), and 3+ (strong) intensity. As appropriate, factor staining intensity was assessed for one or more of tumor cell nucleus, cytoplasm, and membrane. Immunohistochemistry (IHC) scores (0-300) were then calculated for each relevant cell region by multiplying stain intensity (0-3) by percent tumor cells staining with each intensity. For each tumor specimen, results from the three cores were then averaged. If for a given patient results for only a single core were evaluable by IHC, then that single value was used, while the results for two cores were averaged if only two of the three cores were evaluable.
Molecular factors that we assessed included nuclear factors (p53, p21 WAF1/CIP1
, and Ki67), cytoplasmic factors (cyclooxygenase-2 and decoy receptor-2), nuclear and cytoplasmic factors (copper transporter- , and excision repair cross-complementing rodent repair deficiency, complementation group 1 [ERCC1]), and cytoplasmic and membrane carbonic anhydrase IX (mCAIX) and transforming growth factor-β. We also defined number of apoptotic cells (by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end-labeling assay) per 10 high-powered fields, and for a subset of patients, we had information on mutation status for epidermal growth factor receptor (EGFR) and KRAS genes.
Tumor specimens were assessed by pathologists IIW and MIN for tumor histopathologic type, percent of adenocarcinomas made up of acinar, lepidic, mucinous, papillary, solid and micropapillary regions, number of mitoses per 10 high-powered fields, presence of necrosis, and invasion of pleura or lymphovascular structures. Number of nodes examined, number of positive nodes, tumor diameter, and pathologic stage were also recorded.
Statistical Methods
Patient gender, age, race, and smoking history information was recorded and summarized by descriptive statistics. Continuous biomarkers were summarized by mean, SD, median, and range. The difference of biomarkers between/among patient characteristic groups was tested by Wilcoxon ranked sum test or Kruskal-Wallis test, when appropriate. Correlation between biomarkers was assessed using Spearman correlation analysis. Two experienced clinicians (DJS and CB) reviewed patient records and scans to assess TTR and OS from surgery.
For the purposes of this study, TTR was defined as the time from surgery to relapse or last follow-up, with censoring at LFU, at death from other causes, or at diagnosis of a second primary associated with metastases if the patient was clinically relapse free from their initial NSCLC. For example, if a patient was diagnosed with colorectal cancer, with intra-abdominal nodal and liver metastases, this was interpreted for the purposes of this study as representing metastatic colorectal cancer unless there were compelling clinical, radiological, or histopathologic data to indicate that it did instead indicate recurrent lung cancer, and the patient was censored for lung cancer recurrence at the time of diagnosis of the colorectal cancer. Similarly, while development of more than one lung nodule was generally interpreted as recurrence of the original lung cancer, development of a solitary lung nodule or mass that appeared clinically and radiologically to be more likely a new lung cancer primary was coded as a new primary rather than a recurrence. For example, a nodule or mass developing near a resection margin was coded as a recurrence of the original lung cancer, whereas development of a single spiculated nodule in a different lobe was interpreted as a new primary. The investigators were blinded with respect to biological markers when making these designations.
Patients who died of other apparent causes and who had not had clinically suspected or confirmed relapse by the time of death were censored for TTR at their last relapse-free follow-up if they had not had sufficient evaluation shortly before their death to conclude with reasonable clinical certainty that they were free of relapse at the time of death. Again, this designation was done in a blinded fashion. We recognized that in both this designation and in the designation of recurrence versus new primary, we would miss some recurrences, but we chose to err on the side of being more certain of recurrence versus being more certain about lack of recurrence.
TTR and OS were estimated using the Kaplan-Meier method, and the log-rank test was employed to compare TTR between mCAIX staining groups. Cox models were used to assess factors associated with TTR. Only the significant factors with p value of less than 0.05 from univariate Cox model were included in the multicovariate Cox model, and backward selection was used to eliminate the ones that were not significant. p value of less than 0.05 was considered as significant. The analysis was performed using SAS 9.3 (SAS Institute Inc., Cary, NC). Factors associated with TTR in multicovariate analyses were then tested for their association with OS.
RESULTS
The median age of the 230 patients was 68. .4%) and 74.6% (95% CI, 68.6%, 81.2%), respectively. When TTR was replotted as an exponential decay (log-linear) curve and subjected to nonlinear regression analysis as previously described, 6 those on the terminal flat portion of the curve (the "cured" fraction) constituted 70% of the overall population, and the estimated half-life to relapse for the 30% relaps- a As a continuous variable. CAIX, carbonic anhydrase IX; COX2, cyclooxygenase-2; CTR1, copper transporter-1; DNMT1, DNA methyltransferase 1; DcR2, decoy receptor-2; ERCC1, excision repair crosscomplementing rodent repair deficiency, complementation group 1; HIF-1α, hypoxia-inducible factor-1α; Rb, retinoblastoma; SHARP2, enhancer-of-split-and-hairy-related protein; TgF-β, transforming growth factor-β; VEgF, vascular endothelial growth factor. Five N0 patients (3-stage IA patients with tumors measuring 1.6-2.2 cm and 2-stage IB patients, both with tumors measuring 4.5 cm) were judged clinically and radiologically to have developed second primary cancers rather than recurrences. Of these, two patients were negative for mCAIX on IHC and three patients were positive. If they were excluded from the analyses, TTR continued to be significantly associated with mCAIX (HR = 1.903; 95% CI, 1.114-3.250; p = 0.0185). None of the five patients had their new primaries compared with their old ones histopathologically.
We then assessed characteristics that correlated with mCAIX IHC scores. Table 3 presents median mCAIX scores for different patient groups. mCAIX scores were significantly higher in squamous cell carcinomas than in adenocarcinomas, and less differentiated tumors than better differentiated tumors, with a trend toward higher scores (p = 0.074) in patients with EGFR wild-type tumors compared with those with EGFR mutations. There was also a trend toward higher mCAIX scores in patients with higher stage tumors (p = 0.063 for N0 versus N1). Table 4 presents correlations between mCAIX scores and other continuous variables. mCAIX scores correlated directly with tumor diameter, cytoplasmic SHARP2 scores, number of mitoses, tumor necrosis, scores for cytoplasmic SHARP2, and nuclear Ki67, nuclear DNMT1, and nuclear p53 scores, and they correlated inversely with percent of tumor that had papillary characteristics (among adenocarcinomas) and with scores for cytoplasmic HIF-1α, cytoplasmic VEgF, cytoplasmic DNMT1, nuclear and cytoplasmic CTR1, cytoplasmic ERCC1, nuclear and cytoplasmic p16, and nuclear p14. mCAIX scores did not correlate with apoptosis or with scores for nuclear HIF-1α, nuclear VEgF, SHARP2, or other pro-cell-survival or tumor suppressor gene-related factors.
IHC data for mCAIX were evaluable for all three cores for 63.2% of patients, for two cores for 23.4% of patients, and for only one core for 13.4% of patients. Using data from patients in whom at least two cores were evaluable for mCAIX, we also assessed impact of heterogeneity of tumor mCAIX IHC expression on TTR. Whether just considering patients with three evaluable cores (37% mCAIX negative for all cores, 45% mCAIX positive for all cores, and 19% heterogeneous with 1-2 cores negative, and the remaining positive for mCAIX), or also adding in patients with just two evaluable cores (38% mCAIX negative in both cores, 45% positive in both cores, and 17% positive in one and negative in the other), the TTR curve for heterogeneous patients was intermediate between the TTR curves for homogeneously negative patients and for homogeneously positive patients (p = 0.0471, logrank test for trend). If we separately assessed the patients with only a single evaluable core, 47% were negative for mCAIX and 53% were positive. CIs were wide, but TTR was significantly worse for positive patients than for negative patients (HR = 6.413; 95% CI, 1.363-30.17; p = 0.0187). In patients with at least two evaluable cores, the proportion of patients with mCAIX heterogeneity was similar for patients with adenocarcinomas versus squamous carcinomas (17% versus 16%), whereas the proportion of patients with all cores being positive was lower in adenocarcinomas compared with squamous carcinomas (35% versus 60%, p = 0.0007). Similarly, although only 6% of patients with no necrosis noted in their samples had heterogeneity between cores compared with 17% of patients with at least some degree of tumor necrosis, this difference was not significant (p = 0.49), whereas the proportion of patients who had all cores positive for mCAIX was higher in those with necrosis compared with those without necrosis (48% versus 21%, p = 0.0287).
Although we were primarily interested in TTR, we then assessed whether the factors associated with TTR in multicovariate Cox models were also associated with OS. When nodal stage and mCAIX were taken together as the only factors considered for a multicovariate OS model, the HR for N1 versus N0 was 1.918 (95% CI, 1.223, 3.008; p = 0.0133) and the HR for mCAIX positive versus negative was 1.762 (95% CI, 1.142, 2.720; p = 0.0105). The 60-month probability of OS for mCAIX negative/N0 patients, mCAIX positive/N0 patients, mCAIX negative/N1 patients, and mCAIX positive/ N1 patients was 0.745 (95% CI, 0.647, 0.858), 0.639 (95% CI, 0.0.550, 0.742), 0.727 (95% CI, 0.506, 1.0), and 0.272 (95% CI, 0.149, 0.497), respectively (Fig. 2B) .
DISCUSSION
In determining who should be considered for adjuvant therapies, it helps to be able to define those patients who are at highest risk of tumor relapse. In this study, we found that for patients with resected stage I-II NSCLC, there appeared to be a plateau on the TTR curve, with approximately 70% of patients projected to be on this cured plateau. TTR differs from "relapse-free survival" since our patients were censored if they died of other apparent causes, while either relapse or death from any causes is counted as a relapse-free survival event. We wished to maximize the probability of defining factors associated with tumor biology without contamination from factors associated with death from comorbidities or second primary malignancies. Patients who died of uncertain causes without recent reevaluation of relapse status were censored at the time of last evaluation for relapse if they were relapse free at that time. Our approach (designed to improve biological and clinical relevance of our assessments) decreased statistical power by decreasing the number of evaluable "events" and by decreasing the length of follow-up for censored patients and would have missed any relapses occurring after LFU.
In keeping with the well-established impact of stage on outcome, 3 node involvement emerged as the most important predictor of relapse. Presence of membrane staining for carbonic anhydrase IX (CAIX) was the only other factor that correlated with outcome in multicovariate analysis. Although mCAIX correlated with both tumor size and with Ki67, mCAIX correlated independently with TTR while size and Ki67 did not.
CAIX messenger RNA (mRNA) 7, 8 and protein (by IHC) [9] [10] [11] [12] are frequently expressed in resected NSCLCs, with CAIX expression being particularly common in squamous cancers. 9, 13 It is unknown whether this association of CAIX HIF-1α, hypoxia-inducible factor-1α; VEgF, vascular endothelial growth factor; SHARP2, enhancer-of-split-and-hairy-related protein; DNMT1, DNA methyltransferase 1; CTR1, copper transporter-1; TgF-β, transforming growth factor-β; ERCC1, excision repair cross-complementing rodent repair deficiency, complementation group 1; Rb, retinoblastoma.
with squamous lung cancers is related to the frequent loss of the von Hippel-Lindau (VHL) tumor suppressor gene that is seen in NSCLC.
14 VHL loss of heterozygosity 15 and methylation/downregulation 16 are common in NSCLC and occur in squamous cell carcinomas much more frequently than in adenocarcinomas. In other tumor types, mCAIX expression was noted in pheochromocytomas only if they were associated with VHL germline mutations, 17 whereas in renal cell carcinomas, CAIX expression was perinecrotic in tumors with intact VHL systems but was diffuse in VHL-defective tumors. 18 Tumor subtype may also be important. We found particularly low expression in lung adenocarcinomas with a high papillary component. Of interest, CAIX expression is also lower in papillary renal cell carcinomas than that in clear cell kidney carcinomas, 19, 20 and CAIX expression also varies with subtype in ovarian 21 and breast [22] [23] [24] [25] cancers. CAIX catalyzes the reversible hydration of carbon dioxide to carbonic acid and is up-regulated in cancers to help maintain physiologic intracellular pH despite high glycolysis rates. 26 While maintaining a physiologic intracellular pH, it acidifies the extracellular space. 26 CAIX may promote a metastatic or invasive phenotype by reducing cell adhesion, 27 increasing cell invasiveness 28 and mobility and migration, 27 inducing angiogenesis, 27 and activating proteases. 27 CAIX expression in normal tissues is generally substantially less than that in tumors. 7, 8, 12, 13 Hypoxia leads to increased CAIX gene expression, 29 transcription, 30 and protein expression 31, 32 in several types of tumor cell lines, and both low glucose and low bicarbonate increase CAIX transcription and protein expression in hypoxic cells. 30 In resected NSCLC, tumor oxygenation correlated negatively with CAIX IHC staining, 33 although there has not been consistent correlation between tumor hypoxia and CAIX expression in vivo, 32 and for at least some tumor types, there may be both hypoxia-driven and hypoxia-independent CAIX signaling pathways. 34, 35 In keeping with our findings, most (but not all) 36 other NSCLC studies assessing CAIX IHC 11, 13, [37] [38] [39] or mRNA 7, 33, 40 tumor expression or plasma levels 37 have also reported an association of high expression with worse overall 11, 13, 33, 37, 38, 40 or disease-free 7, 13, 33, 39 survival, with the greatest negative impact on survival being noted in later stage NSCLCs and in squamous cell carcinomas. 33 Although we found the strongest correlation between mCAIX staining and TTR, others had previously noted perinuclear CAIX staining to be particularly important. 11, 38 High tumor cell CAIX expression has also been associated with worse prognosis in sarcomas, 41, 42 gliomas, 28, 43 neuroblastomas, 44 papillary renal cell carcinomas, 45 and carcinomas of the breast, 23, 24, 46, 47 head and neck, 48 nasopharynx, 49 ovary, 21 cervix, 50 and rectum, 51 but CAIX expression did not correlate with outcome in meningiomas 52 or in carcinomas of the pancreas 53 or prostate 54 and was paradoxically associated with improved outcome in renal clear cell carcinomas. 19, 55, 56 High CAIX levels in tumor stromal cells may also be associated with poor outcome. 57, 58 In our study, mCAIX expression correlated with tumor size, with markers of proliferation (including Ki67 and number of mitoses), with poor differentiation, and with necrosis (but not apoptosis), and we noted a trend (p = 0.063) toward higher mCAIX expression in N1 versus N0 tumors. Other studies that included a variety of tumor types also noted a correlation of CAIX expression with tumor size, 47, 50 CAIX and VEGF are both target genes of the transcription factor HIF-1α 63, 64 that is generally induced by hypoxia but that may also be induced by Src. 64 Although mCAIX expression in our patients did correlate with cytoplasmic expression of the hypoxia-inducible factor SHARP2, it did not correlate with HIF-1α or VEgF nuclear expression but paradoxically correlated inversely with HIF-1α and VEgF cytoplasmic expression. Results have been variable in other studies. In various tumor types, CAIX expression has correlated with HIF-1α expression in some studies 39, 43, 47, 49, 52, 65 but not in others. 61, 65, 66 HIF-1α may also lose its transcriptional ability (e.g., through repression by p53) such that CAIX induction does not happen despite high HIF-1α expression. 67 Furthermore, CAIX expression may correlate with HIF-1α expression in tumors in which the HIF-1α expression is perinecrotic but not in tumors in which HIF-1α expression is diffuse throughout the tumor. 60 Also, CAIX has a much longer half-life in tissues (approximately 38 hr) 30 than does HIF-1α, and HIF-1α expression will rapidly decrease in tumor areas that have low nutrient levels, whereas CAIX will persist due to its longer half-life. 68 In addition, in the absence of hypoxia and HIF-1α, CAIX expression may be up-regulated by high cell density through the PI3K pathway, 69 and increased expression of CAIX in the absence of hypoxia may also occur with hypomethylation of the CAIX gene promoter. 70 Similarly, some previous studies have found positive correlations between CAIX and VEgF expression, 33, 43, 52, 59 whereas others have not, 34, 50, 71 and still others have found an inverse correlation between CAIX and VEgF expression, 56 similar to what we found. Lack of a consistent correlation between CAIX and VEgF may be due in part to the fact that upon reoxygenation of tissues, VEgF mRNA declines rapidly, whereas CAIX mRNA expression persists for more than 72 hours. 59 In addition to serving as a prognostic marker, CAIX could also potentially serve as a therapeutic target or as a predictive marker for efficacy of other therapies. Therapies targeting CAIX were effective in preclinical models, 27 and some are in early stages of clinical investigation. 72 Moreover, high CAIX expression in NSCLC may be associated with decreased efficacy of radiotherapy, 9 and interference with CAIX strongly augments the efficacy of both radiotherapy and some chemotherapy agents in preclinical systems. 28 Conversely, activity of targeted agents and cytokines may be augmented in renal cell carcinomas with high CAIX expression, 73 and tumor uptake and efficacy of some chemotherapy agents that are weak acids could potentially be augmented by the acidic milieu promoted by CAIX. 74 In summary, high CAIX expression is associated with poor prognosis across a wide range of tumor types, and we found that mCAIX expression in particular was associated with an increased risk of relapse in our stage I-II NSCLC patients. Based on these observations, it would be reasonable to assess mCAIX expression further as a prognostic factor in NSCLC, and given the range of studies that have found an association between CAIX expression and poor outcome in NSCLC, it would be reasonable in advanced NSCLC to assess efficacy of new investigational agents targeting CAIX.
